Greenwoods Asset Management Ltd lifted its stake in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 42.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 351,531 shares of the company’s stock after purchasing an additional 104,000 shares during the quarter. Intellia Therapeutics accounts for 1.0% of Greenwoods Asset Management Ltd’s holdings, making the stock its 8th biggest holding. Greenwoods Asset Management Ltd’s holdings in Intellia Therapeutics were worth $10,061,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Macquarie Group Ltd. acquired a new stake in Intellia Therapeutics in the second quarter valued at about $101,000. Patriot Financial Group Insurance Agency LLC acquired a new stake in Intellia Therapeutics in the third quarter valued at about $116,000. Nikko Asset Management Americas Inc. acquired a new stake in Intellia Therapeutics in the third quarter valued at about $141,000. Legal & General Group Plc boosted its stake in Intellia Therapeutics by 75.4% in the second quarter. Legal & General Group Plc now owns 5,427 shares of the company’s stock valued at $149,000 after buying an additional 2,333 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Intellia Therapeutics by 519.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,733 shares of the company’s stock valued at $157,000 after buying an additional 4,807 shares in the last quarter. 67.80% of the stock is currently owned by institutional investors.
Several analysts recently weighed in on the company. Raymond James assumed coverage on Intellia Therapeutics in a research note on Thursday, September 20th. They issued a “market perform” rating on the stock. BidaskClub raised Intellia Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, September 15th. Chardan Capital reaffirmed a “buy” rating and issued a $57.50 price objective on shares of Intellia Therapeutics in a research note on Friday, August 24th. ValuEngine lowered Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, September 22nd. Finally, Cann reissued a “hold” rating on shares of Intellia Therapeutics in a research note on Thursday, October 18th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $33.42.
Shares of NTLA stock opened at $16.41 on Thursday. Intellia Therapeutics Inc has a 12 month low of $15.70 and a 12 month high of $35.99. The stock has a market cap of $712.51 million, a PE ratio of -8.73 and a beta of 3.88.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Wednesday, October 31st. The company reported ($0.53) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.05). Intellia Therapeutics had a negative net margin of 308.81% and a negative return on equity of 31.70%. The firm had revenue of $7.41 million for the quarter, compared to analyst estimates of $11.58 million. During the same period in the previous year, the business posted ($0.44) earnings per share. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Sell-side analysts anticipate that Intellia Therapeutics Inc will post -2.09 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Greenwoods Asset Management Ltd Grows Stake in Intellia Therapeutics Inc (NTLA)” was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://transcriptdaily.com/2018/12/06/greenwoods-asset-management-ltd-grows-stake-in-intellia-therapeutics-inc-ntla.html.
Intellia Therapeutics Profile
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Featured Article: What are Institutional Investors?
Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics Inc (NASDAQ:NTLA).
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.